October 29, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Farrukh Awan has done research on the cardiac side effects...
October 22, 2019 Dear Friends and Supporters of the CLL Society, New this week! We have been asked to provide some advice on vaccines so...
October 8, 2019 Dear Friends and Supporters of the CLL Society, New this week! Designing the right trials for all patients takes careful planning, deep...
October 1, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Wiestner of the NIH discusses the importance of acalabrutinib’s ability...
September 24, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Furman discusses how he decides on what single drug or combination of...
September 17, 2019 Dear Friends and Supporters of the CLL Society, New this week! The trial that compared FCR to ibrutinib and rituximab for treatment...
September 10, 2019 Dear Friends and Supporters of the CLL Society, New this week! We need to know the total cost of therapies, but it...
September 3, 2019 Dear Friends and Supporters of the CLL Society, We invite you to attend our CLL Society Webinar Tuesday, Sep 10, 2019,...
August 27, 2019 Dear Friends and Supporters of the CLL Society, We invite you to attend our CLL Society Webinar Tuesday, Sep 10, 2019,...
August 20, 2019 Dear Friends and Supporters of the CLL Society, We invite you to attend our CLL Society Webinar Tuesday, Sep 10, 2019,...
August 13, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Koffman’s article, "Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy...
August 6, 2019 Dear Friends and Supporters of the CLL Society, New this week! Lorna Warwick is the CEO of the Lymphoma Coalition. At ASH...
